Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates

Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary Endpoint Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis IND

AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

SAN DIEGO , Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized,

AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

  Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study   Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy   Patients demonstrated rapid and sustained mJDA score